Million A. Tegenge

Center for Biologics Evaluation and Research

Also affiliated with United States Food and Drug Administration, Center for Drug Evaluation and Research

Immunology and MicrobiologyMedicinePharmacology, Toxicology and PharmaceuticsMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma”.

FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1035

N/A

0.292DataRank · unranked

6 citations

Upendra Mahat, Nicholas C. Richardson, Million A. Tegenge, Qianmiao Gao, Marc R. Theoret +2 more

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0880

N/A

0DataRank · unranked

14 citations

Chaohong Fan, Peter Bross, Asha Das, Elin S. Cho, Karin M. Knudson +6 more

Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives

The AAPS Journal(2025)10.1208/s12248-025-01155-1

N/A

0DataRank · unranked

8 citations

Osman N. Yoğurtçu, Artur Belov, Xiaofei Wang, Richard A. Forshee, Million A. Tegenge